The present invention relates to the treatment of brain or neurologic disorders. In this study, the inventors hypothesized that a Fc receptor (FcRn) […]
Anemia, defined as a decreased quantity of circulating functional red blood cells, is a major source of morbidity and mortality affecting a-third of […]
In the present invention, inventor identified the hepatokine FGL1 as a previously undescribed suppressor of hepcidin that is highly induced in the […]
The present invention relates to regulatory T cell and uses thereof. By their immunosuppressive and anti-inflammatory activities, regulatory T cells […]
GPR50 (also known as MMR, H9 or ML1X), is an orphan G protein-coupled receptorbelonging to the melatonin receptor family, but which has lost the […]
The present invention relates to a method for preventing or treating a cancer disease by targeting the epigenetic factor Chromodomain on Y-like 2 […]
Inventors have shown that targeting DDR1 and DDR2 collagen receptors by Imatinib resensitizes melanoma tumors to BRAFV600E to targeted therapy and […]
The invention relates to a CDC25A phosphatase inhibitor for use in the treatment of drug resistant cancer or for use in the prevention of tumor […]
Upon activation, mast cells rapidly release preformed inflammatory mediators from large cytoplasmic granules via regulated exocytosis. This acute […]
The invention is in the field of therapy of gut inflammatory diseases such as Inflammatory Bowel Diseases (IBD) or Irritable Bowel Syndrome (IBS) […]